Idelalisib (Standard)

Idelalisib (Standard) is the analytical standard of Idelalisib. This product is intended for research and analytical applications. Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable p110δ inhibitor with an IC50 of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.

Product Specifications

CAS Number

[870281-82-6]

UNSPSC

12352100

Target

Autophagy; PI3K; Reference Standards

Related Pathways

Autophagy; Others; PI3K/Akt/mTOR

Field of Research

Cancer

Smiles

O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)CC)=NC5=C1C(F)=CC=C5

Molecular Formula

C22H18FN7O

Molecular Weight

415.42

References & Citations

[1]Lannutti BJ, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood, 2011, 117 (2), 591-594.|[2]Herman SE, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood, 2010, 116 (12), 2078-2088.|[3]Low PC, et al. PI3Kδ inhibition reduces TNF secretion and neuroinflammation in a mouse cerebral stroke model. Nat Commun. 2014 Mar 14;5:3450.|[4]Cooney J, et al. Synergistic targeting of the regulatory and catalytic subunits of PI3Kδ in mature B cell malignancies. Clin Cancer Res. 2018 Mar 1;24 (5) :1103-1113.